A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

Clinical trial NCT02462811 · COMPLETED

Trial details

NCT number: NCT02462811
Sponsor: Joseph Hazelton
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Pain Nausea Vomiting

Start date: 2014-09-01
Primary completion: 2015-07-01
Enrollment: 552

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.